Alkhudair Nora, Alhifany Abdullah A, Alsubaie Basha, Alshubaiki Leena, Alrajhi Abdullah M, Alnuhait Mohammed
Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Department of Pharmacy Practice, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Saudi Pharm J. 2023 Dec;31(12):101840. doi: 10.1016/j.jsps.2023.101840. Epub 2023 Oct 21.
Formulary drug list is a continually updated list of medications routinely stocked by hospitals and other healthcare facilities and deemed effective, safe, and cost saving. Non-formulary drug (NFD) refers to medications not on the formulary, due to cost or lack of clinical data. This study aimed to examine the processing of NFD requests by oncology providers (OPs) in Saudi Arabia.
A cross-sectional survey in Saudi oncology centers gathered perspectives of healthcare practitioners, mainly oncology pharmacists and physicians, on NFDs and request processes, aiming to understand variations, reasons for NFDs, and suggestions for an improved, unified NFDs request algorithm.
A total of 93 physicians and pharmacists responded, 57 % were pharmacists, 43 % were physicians, and 94.6 % worked in the governmental sector. Around 31.2 % reported that it takes one week to receive a decision on their NFD request, while 28 % reported it takes two weeks to one month. Furthermore, 35.5 % of participants reported that the complete NFD process, from the initial order placement to the receipt of medications, spans a duration of 2-4 months, while 8.6 % noted a longer duration exceeding six months. The participants reported that the most common obstacles while requesting NFD were procurement delays and lengthy processing times. Additionally, 26.9 % agreed that formulary restrictions hindered medical care and 40.3 % reported delays in patient care. While 33.8 % were forced to use fewer effective options, and 22.1 % referred patients to palliative care.
The current practice of NFDs has negative consequences on cancer patient outcomes due to delays in patient care or the use of less effective drugs. Thus, we recommend having a national NFD access program.
处方药物清单是医院和其他医疗机构定期储备的不断更新的药物清单,这些药物被认为有效、安全且具有成本效益。非处方药物(NFD)是指由于成本或缺乏临床数据而未列入处方清单的药物。本研究旨在调查沙特阿拉伯肿瘤学提供者(OPs)对非处方药物请求的处理情况。
在沙特肿瘤中心进行的一项横断面调查收集了医疗从业者,主要是肿瘤药剂师和医生,对非处方药物及其请求流程的看法,旨在了解差异、非处方药物的原因以及改进和统一非处方药物请求算法的建议。
共有93名医生和药剂师做出回应,其中57%是药剂师,43%是医生,94.6%在政府部门工作。约31.2%的人报告说,他们的非处方药物请求需要一周时间才能得到决定,而28%的人报告说需要两周到一个月的时间。此外,35.5%的参与者报告说,从最初下单到收到药物的整个非处方药物流程持续2至4个月,而8.6%的人指出持续时间超过六个月。参与者报告说,请求非处方药物时最常见的障碍是采购延迟和处理时间过长。此外,26.9%的人同意处方限制阻碍了医疗护理,40.3%的人报告了患者护理的延迟。虽然33.8%的人被迫使用效果较差的选择,22.1%的人将患者转诊至姑息治疗。
由于患者护理延迟或使用效果较差的药物,目前非处方药物的做法对癌症患者的治疗结果产生了负面影响。因此,我们建议制定一项全国性的非处方药物获取计划。